| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SETDB1 |
| Uniprot No | Q15047 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-397aa |
| 氨基酸序列 | MSSLPGCIGLDAATATVESEEIAELQQAVVEELGISMEELRHFIDEELEKMDCVQQRKKQLAELETWVIQKESEVAHVDQLFDDASRAVTNCESLVKDFYSKLGLQYRDSSSEDESSRPTEIIEIPDEDDDVLSIDSGDAGSRTPKDQKLREAMAALRKSAQDVQKFMDAVNKKSSSQDLHKGTLSQMSGELSKDGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLVLFFSTILEAEVGGGGT |
| 预测分子量 | 44.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SETDB1重组蛋白的3篇参考文献的简要列举：
---
1. **文献名称**：*SETDB1: a novel KAP-1-associated histone H3. lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes*
**作者**：Schultz, D.C. et al.
**摘要**：该研究首次报道了SETDB1作为H3K9特异性组蛋白甲基转移酶的功能，发现其通过与KRAB-ZFP/KAP-1复合物相互作用参与异染色质形成，并利用重组蛋白实验证明其介导基因沉默的机制。
---
2. **文献名称**：*Structural and functional analysis of the human histone methyltransferase SETDB1*
**作者**：Matsui, T. et al.
**摘要**：通过重组表达人源SETDB1蛋白，研究揭示了其催化结构域的活性依赖辅助因子ATF7IP，并证明SETDB1的H3K9三甲基化功能在哺乳细胞基因沉默中的关键作用。
---
3. **文献名称**：*The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset*
**作者**：Ceol, C.J. et al.
**摘要**：该研究利用重组SETDB1蛋白进行功能验证，发现其在黑色素瘤中过表达可诱导致癌基因沉默并促进肿瘤发生，强调了SETDB1作为癌症治疗靶点的潜力。
---
4. **文献名称**：*Tudor domain of SETDB1 recognizes methylated H4K20 but not H3K9 trimethylation*
**作者**：Kim, J. et al.
**摘要**：通过重组SETDB1的Tudor结构域蛋白，阐明了其特异性识别H4K20甲基化而非H3K9甲基化的分子机制，扩展了对SETDB1表观遗传调控多样性的理解。
---
这些文献涵盖了SETDB1重组蛋白的功能机制、结构解析及疾病关联研究。
SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1) is a crucial epigenetic regulator belonging to the SUV39 subfamily of histone methyltransferases. It catalyzes the addition of methyl groups to lysine 9 of histone H3 (H3K9), predominantly generating H3K9 trimethylation (H3K9me3), a hallmark of transcriptionally repressive heterochromatin. This enzyme plays a central role in gene silencing, genomic stability, and chromatin organization by recruiting co-repressor complexes through its methyltransferase activity. Structurally, SETDB1 contains an N-terminal Tudor domain for protein-protein interactions, a pre-SET domain critical for catalytic function, and a C-terminal methyltransferase SET domain. Its activity is tightly regulated by post-translational modifications and interaction partners like ATF7IP, which stabilizes and directs its nuclear localization.
Recombinant SETDB1 proteins are engineered for in vitro studies to dissect its enzymatic mechanisms and interactions. These proteins are typically expressed in heterologous systems (e.g., insect or mammalian cells) to ensure proper folding and post-translational modifications. Tagged versions (e.g., FLAG, GST, or His-tag) facilitate purification and experimental tracking. Researchers employ recombinant SETDB1 to investigate its role in X-chromosome inactivation, retroelement silencing, and cancer biology, where its dysregulation is linked to tumorigenesis through aberrant silencing of tumor suppressors or oncogene activation. Recent studies also highlight its potential as a therapeutic target in neurodegenerative diseases and viral latency. The development of active recombinant SETDB1 has accelerated high-throughput screening for inhibitors and mechanistic studies of chromatin remodeling.
×
